Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bevacizumab + Trifluridine-tipiracil hydrochloride |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bevacizumab | Avastin | VEGF Antibody 12 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
Trifluridine-tipiracil hydrochloride | Lonsurf | TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005 | Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (PMID: 29226002). Lonsurf (trifluridine/tipiracil hydrochloride) is FDA-approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma, and in combination with Avastin (bevacizumab) in patients with previously-treated metastatic colorectal cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04737187 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) | Completed | USA | POL | ITA | HUN | FRA | ESP | DNK | DEU | BRA | BEL | AUT | 3 |
NCT05007132 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | Recruiting | DEU | 0 |
NCT02654639 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT06614192 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride ABBV-400 | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | Recruiting | USA | ISR | 1 |
NCT06522919 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Pembrolizumab | Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax) | Not yet recruiting | ITA | 0 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |